Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone

Haematologica. 2009 Dec;94(12):1777-8. doi: 10.3324/haematol.2009.009118. Epub 2009 Oct 8.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Adult
  • Chelation Therapy / methods*
  • Deferiprone
  • Deferoxamine / therapeutic use*
  • Drug Therapy, Combination
  • Female
  • Humans
  • Iron
  • Iron Chelating Agents / therapeutic use
  • Male
  • Middle Aged
  • Multivariate Analysis
  • Pyridones / therapeutic use*
  • Siderophores / therapeutic use
  • Survival Analysis
  • Time Factors
  • Young Adult
  • beta-Thalassemia / blood
  • beta-Thalassemia / drug therapy*

Substances

  • Iron Chelating Agents
  • Pyridones
  • Siderophores
  • Deferiprone
  • Iron
  • Deferoxamine